Trial reportNaunyn-Schmiedeberg's archives of pharmacology2026
Pharmacokinetic comparison of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg fixed-dose combination versus coadministration of separate tablets in healthy participants.
Trial report in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the pharmacokinetics (PKs) for fixed-dose combination (FDC) of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg (test) compared to separate tablets of ezetimibe/rosuvastatin 10/20 mg FDC and telmisartan 80 mg (reference). A randomized, open-label, 4-period, 2-sequence replicated crossover study was conducted in healthy participants. Each treatment group received a single oral dose of test or reference drug in each period. PK samples during the 1st and 2nd periods were collected for all three drugs, while only telmisartan concentration was measured in the 3rd and 4th periods to evaluate intra-subject variability (ISV) of telmisartan. Geometric mean ratios (GMRs) of PK parameters and their 90% confidence intervals (CIs) were calculated with a linear mixed effect model between each treatment group. To account for the high ISV of telmisartan's peak plasma concentration (C
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.